# Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

> **NCT04285723** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- PIK3CA-Related Overgrowth Spectrum (PROS)

## Interventions

- **OTHER:** alpelisib

## Key facts

- **NCT ID:** NCT04285723
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-09
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-04-16
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04285723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04285723, "Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04285723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*